Similarly, we found evidence for a protective effect of higher genetically predicted ASAT on risks of luminal B/HER2-negative-like and triple-negative or basal-like breast cancer, and yet there was evidence for increased risk of endometrial, liver, esophageal adenocarcinoma, and ovarian cancer. The gene discussed is ERBB2; the disease is breast carcinoma.